RBM39 and acute myeloid leukemia: In AML, the effects of RBM39 deletion on splicing further lead to preferential lethality for AML with spliceosome mutations, which provides a strategy for the treatment of those carrying RBP-splicing mutations (Wang E. et al., 2019; Villanueva et al., 2020).